The following is a summary of “Optimal PSA density threshold for prostate biopsy in benign prostatic obstruction patients ...

Investigators assessed whether MRI alone can identify all cases of Gleason grade group 2 or higher disease in patients on prostate cancer active surveillance.

Investigations: Physical examination, laboratory evaluation,endorectal MRI of the prostate, cystoscopy and biopsy. Diagnosis: Poorly differentiated adenocarcinoma of theprostate, with invasion of ...

The following is a summary of “Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic ...

Bill Faulkner had long approached prostate cancer testing with skepticism. For almost a decade, the 73-year-old had avoided ...

A new study published in the journal of Research and Reports in Urology showed that lesion size was a crucial predictor of ...

The global fusion biopsy market, valued at US$0.61 billion in 2023, is forecasted to grow at a robust CAGR of 7.1%, reaching ...

The Global Fusion Biopsy Market Size is projected to grow at a CAGR of 8.9% from 2025 to 2032, according to a new report published by Verified Market Research®. The report reveals that the market was ...

However, the harms of screening can be mitigated by the use of urinary and/or blood-based biomarkers, with or without MRI, to better select men who should proceed to prostate biopsy. Advances in ...

MRI should be considered an adjunct to, and not a replacement for, biopsies for men on active surveillance for prostate cancer. MRI does not consistently rule out the presence of Gleason grade ...